Switch To Branded denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for switch to branded are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied a Switch to the Branded Version as Duplicate Therapy — and How to Appeal

When your prescriber requests the branded version of a drug you are already receiving as a generic or biosimilar, Humana may deny it as "duplicate therapy" — arguing that you are already being treated with a therapeutically equivalent product. This denial logic is common but flawed in specific clinical situations: not all branded and generic formulations behave identically in every patient, and documented failure of or intolerance to one form is a recognized medical basis for switching.

## Why This Denial Is Appealable

A duplicate-therapy denial implicitly assumes clinical interchangeability that may not apply to your case. If your prescriber has documented a specific reason the branded formulation is medically necessary — such as a documented adverse response to the generic, instability on the substituted product, or a condition requiring a formulation characteristic unique to the branded version — that is a substantive medical-necessity argument, not mere preference.

Your appeal rights under federal law: - ACA §2719 / ERISA §503 internal appeal: File within 180 days of the denial. The plan must provide a full-and-fair review that evaluates your individual clinical circumstances. - External review: After exhausting internal appeal, an independent review organization (IRO) can reverse the decision. The external-review window is generally up to four months from final internal denial. - Expedited review (72 hours): Available when the standard timeline would seriously jeopardize your health.

## What to Gather

• Treatment timeline: Dates and outcomes on the generic/biosimilar version — specifically any documented adverse effects, loss of response, or therapeutic failures.
• Prescriber medical-necessity letter: Must explain why the branded formulation is not duplicative — i.e., what clinical distinction makes it necessary for this patient.
• Chart notes documenting the problem: Objective records (lab values, symptom documentation, adverse event notes) corroborating the prescriber's reasoning.
• Humana's coverage policy: Request the current formulary and any medical policy covering therapeutic substitution for this drug class. Note the exception criteria.

## Criteria-Mapping Structure

| Humana Policy Requirement | Supporting Documentation | |---|---| | Diagnosis requiring this drug class | Diagnosis confirmation from chart | | Documentation of trial of formulary alternative | Dates, dose range, and outcome on generic/biosimilar | | Clinical reason branded version is not duplicative | Prescriber letter citing specific formulation distinction or documented failure |

Your appeal letter should directly refute the "duplicate" label by naming the clinical difference the prescriber identified. Attach the relevant chart notes. If Humana upholds the denial, proceed to external review — IROs are well-positioned to evaluate whether a formulary substitution was truly clinically equivalent in your case.